Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
ISIN : US60770K1079
Compare
Compare
Traded in other countries / regions
MRNA.USA0A45.UKM1RN34.Brazil0QF.Germany1MRNA.ItalyMRNA.MexicoMRNA.Austria0QF.BulgariaMRNA_KZ.KazakhstanMRNA.Peru Index Membership
S&P 500Russell 1000Russell 3000NASDAQ 100 IPO Date
2018-12-07Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.02 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.51 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -41.3 | |||||
| 3-Year Book Growth Rate | -7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 18.45 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.44 | |||||
| 9-Day RSI | 67.72 | |||||
| 14-Day RSI | 60.81 | |||||
| 3-1 Month Momentum % | -2.21 | |||||
| 6-1 Month Momentum % | -36.12 | |||||
| 12-1 Month Momentum % | -77.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.22 | |||||
| Quick Ratio | 4.14 | |||||
| Cash Ratio | 3.73 | |||||
| Days Inventory | 67.64 | |||||
| Days Sales Outstanding | 53.49 | |||||
| Days Payable | 73.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.4 | |||||
| Shareholder Yield % | 1.65 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.55 | |||||
| Operating Margin % | -118.8 | |||||
| Net Margin % | -106.95 | |||||
| EBITDA Margin % | -101.78 | |||||
| FCF Margin % | -128.51 | |||||
| ROE % | -29.23 | |||||
| ROA % | -22.36 | |||||
| ROIC % | -48.68 | |||||
| 3-Year ROIIC % | 198.7 | |||||
| ROC (Joel Greenblatt) % | -111.47 | |||||
| ROCE % | -26.34 | |||||
| Years of Profitability over Past 10-Year | 2 | |||||
| Moat score | 8 | |||||
| Tariff score | 4 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.8 | |||||
| PB Ratio | 1.16 | |||||
| Price-to-Tangible-Book | 1.18 | |||||
| EV-to-EBIT | -1.73 | |||||
| EV-to-Forward-EBIT | -1.39 | |||||
| EV-to-EBITDA | -1.84 | |||||
| EV-to-Forward-EBITDA | -1.47 | |||||
| EV-to-Revenue | 1.87 | |||||
| EV-to-Forward-Revenue | 2.9 | |||||
| EV-to-FCF | -1.45 | |||||
| Price-to-GF-Value | 1.19 | |||||
| Price-to-Projected-FCF | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 2.84 | |||||
| Price-to-Net-Cash | 3.51 | |||||
| Earnings Yield (Greenblatt) % | -57.8 | |||||
| FCF Yield % | -34.45 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers